Roche to make decision on novel hedgehog pathway inhibitor in ovarian cancer
This article was originally published in Scrip
Executive Summary
Roche (Genentech) is deliberating whether to continue development of the novel hedgehog pathway inhibitor GDC-0449 in advanced ovarian cancer, following preliminary results from a Phase II trial.